ICUI - ICU Medical Inc Stock Price, Fair Value and News

97.76USD+1.38 (+1.43%)Market Closed

Market Summary

USD97.76+1.38

Market Closed

1.43%

ICUI Stock Price

View Fullscreen

ICUI RSI Chart

ICUI Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-79.59

Price/Sales (Trailing)

1.04

EV/EBITDA

51.83

Price/Free Cashflow

28.67

ICUI Price/Sales (Trailing)

ICUI Profitability

Operating Margin

32.96%

EBT Margin

-2.79%

Return on Equity

-1.4%

Return on Assets

-0.68%

Free Cashflow Yield

3.49%

ICUI Fundamentals

ICUI Revenue

Revenue (TTM)

2.3B

Rev. Growth (Yr)

1.7%

Rev. Growth (Qtr)

6.24%

ICUI Earnings

Earnings (TTM)

-29.7M

Earnings Growth (Yr)

-10.37%

Earnings Growth (Qtr)

-336.9%

Breaking Down ICUI Revenue

Last 7 days

1.5%

Last 30 days

-0.4%

Last 90 days

5.0%

Trailing 12 Months

-46.7%

How does ICUI drawdown profile look like?

ICUI Financial Health

Current Ratio

2.53

Debt/Equity

0.75

Debt/Cashflow

0.1

ICUI Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-1.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.3B	2.3B	2.2B	2.3B
2022	1.5B	1.8B	2.0B	2.3B
2021	1.3B	1.3B	1.3B	1.3B
2020	1.3B	1.3B	1.3B	1.3B
2019	1.4B	1.3B	1.3B	1.3B
2018	1.4B	1.4B	1.4B	1.4B
2017	537.3M	772.0M	1.0B	1.3B
2016	350.0M	363.0M	374.1M	379.4M
2015	317.5M	322.6M	331.2M	341.7M
2014	312.6M	312.7M	307.3M	309.3M
2013	315.7M	317.0M	318.4M	313.7M
2012	306.2M	305.7M	310.7M	316.9M
2011	290.7M	299.9M	300.9M	302.2M
2010	238.4M	253.6M	275.1M	283.0M
2009	214.4M	219.2M	218.4M	229.0M
2008	192.3M	196.4M	200.6M	204.7M
2007	0	0	0	188.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ICU Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	sanzone virginia ruth	sold (taxes)	-87,291	98.08	-890	vp, general counsel
Mar 15, 2024	jain vivek	sold (taxes)	-261,972	98.08	-2,671	chairman and ceo
Mar 15, 2024	woolson daniel	sold	-77,732	98.2715	-791	vp, gm-infusion capital
Mar 15, 2024	sousa ben	acquired	-	-	1,299	chief information officer
Mar 15, 2024	voigtlander christian b.	sold (taxes)	-174,582	98.08	-1,780	chief operating officer
Mar 15, 2024	sanzone virginia ruth	acquired	-	-	1,624	vp, general counsel
Mar 15, 2024	sousa ben	sold (taxes)	-45,411	98.08	-463	chief information officer
Mar 15, 2024	jain vivek	acquired	-	-	4,871	chairman and ceo
Mar 15, 2024	bonnell brian michael	acquired	-	-	3,247	chief financial officer
Mar 15, 2024	bonnell brian michael	sold (taxes)	-174,582	98.08	-1,780	chief financial officer

Which funds bought or sold ICUI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	reduced	-96.62	-1,343,460	39,198	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	34.91	922,048	2,963,430	-%
Apr 22, 2024	Boston Trust Walden Corp	added	28.54	10,140,000	36,605,800	0.26%
Apr 19, 2024	Maryland State Retirement & Pension System	reduced	-0.71	-37,293	852,687	0.02%
Apr 19, 2024	Financial Perspectives, Inc	unchanged	-	76.00	1,073	-%
Apr 19, 2024	State of Alaska, Department of Revenue	reduced	-0.95	82,000	1,326,000	0.01%
Apr 18, 2024	Park Place Capital Corp	unchanged	-	76.00	1,073	-%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	76.00	1,073	-%
Apr 18, 2024	SJS Investment Consulting Inc.	unchanged	-	15.00	215	-%
Apr 18, 2024	Hexagon Capital Partners LLC	added	477	4,683	5,581	-%

Are Funds Buying or Selling ICUI?

Are funds buying ICUI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ICUI

No. of Funds

Unveiling ICU Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 01, 2024	smiths group plc	6.9%	1,670,000	SC 13D/A
Feb 13, 2024	janus henderson group plc	10.8%	2,617,933	SC 13G/A
Feb 13, 2024	fuller & thaler asset management, inc.	6.10%	1,472,050	SC 13G
Feb 08, 2024	wellington management group llp	6.53%	1,575,456	SC 13G/A
Jan 24, 2024	blackrock inc.	10.6%	2,558,515	SC 13G/A
Jan 10, 2024	vanguard group inc	10.11%	2,440,729	SC 13G/A
Dec 11, 2023	t. rowe price investment management, inc.	4.9%	1,173,610	SC 13G/A
Dec 06, 2023	blackrock inc.	10.4%	2,503,520	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	10.1%	2,423,228	SC 13G/A
Feb 10, 2023	janus henderson group plc	10.7%	2,557,226	SC 13G/A

Recent SEC filings of ICU Medical Inc

View All Filings

Date Filed	Form Type	Document
Apr 02, 2024	ARS	ARS
Apr 02, 2024	DEF 14A	DEF 14A
Apr 02, 2024	DEFA14A	DEFA14A
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 15, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to ICU Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.7B	40.1B	-2.69%	-2.54%	32.62	4.65	-8.12%	-17.45%
BDX	67.7B	19.5B	-4.86%	-10.59%	53.89	3.47	4.02%	-22.04%
ALGN	23.4B	3.9B	-2.36%	-14.10%	52.63	6.06	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.84	1.41	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.48	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.02%	16.40%	32.52	2.65	4.97%	18.89%
BIO	8.3B	2.7B	-18.63%	-38.25%	-13.07	3.12	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.58	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-558.61	9.25	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.02	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	383.0M	166.7M	1.30%	-3.37%	-4.63	2.3	6.67%	-456.34%
ANGO	241.5M	324.0M	12.50%	-31.24%	-1.26	0.75	-3.19%	-337.41%
APYX	45.7M	52.3M	5.60%	-56.15%	-2.44	0.87	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.32	1.06	5.77%	8.23%

ICU Medical Inc News

Latest updates

ICU Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	6.2%	588	553	549	569	578	598	561	543	341	336	322	318	320	319	303	329	316	307	312	331	340
Cost Of Revenue	-100.0%	-	369	357	377	-	411	393	374	-	208	198	205	-	205	197	207	-	189	208	196	206
Gross Profit	-6.7%	172	184	192	192	175	186	168	169	127	128	124	113	120	114	106	121	114	119	104	135	135
Operating Expenses	14.1%	184	161	190	183	175	187	168	211	104	89.00	89.00	86.00	93.00	88.00	87.00	95.00	96.00	86.00	78.00	105	144
S&GA Expenses	4.0%	155	149	151	153	143	153	159	153	81.00	75.00	74.00	72.00	74.00	71.00	67.00	72.00	71.00	66.00	68.00	73.00	77.00
R&D Expenses	7.4%	22.00	21.00	22.00	20.00	23.00	23.00	23.00	24.00	13.00	12.00	11.00	11.00	12.00	10.00	10.00	11.00	13.00	12.00	11.00	13.00	14.00
EBITDA Margin	-43.1%	0.03*	0.05*	0.14*	0.13*	0.13*	0.19*	0.18*	0.17*	0.17*	0.17*	0.16*	0.15*	-	-	-	-	-	-	-	-	-
Interest Expenses	-786.8%	-166	24.00	24.00	23.00	-112	18.00	15.00	13.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Taxes	-55.0%	-19.53	-12.60	-12.93	-3.58	-5.91	-8.10	-9.38	-16.73	3.00	7.00	6.00	3.00	4.00	1.00	2.00	4.00	0.00	6.00	5.00	2.00	-5.13
Earnings Before Taxes	100.0%	-	-5.37	-22.86	-13.39	-	-21.31	-16.85	-54.80	-	38.00	35.00	27.00	30.00	26.00	21.00	20.00	21.00	33.00	28.00	33.00	-12.48
EBT Margin	0.4%	-0.03*	-0.03*	0.06*	0.06*	0.06*	0.06*	0.07*	0.08*	0.10*	0.10*	0.09*	0.08*	-	-	-	-	-	-	-	-	-
Net Income	-336.9%	-17.15	7.00	-9.93	-9.81	-15.54	-13.21	-7.47	-38.07	20.00	31.00	28.00	24.00	26.00	25.00	19.00	17.00	21.00	27.00	23.00	31.00	-7.35
Net Income Margin	-5.3%	-0.01*	-0.01*	-0.02*	-0.02*	-0.03*	-0.02*	0.00*	0.03*	0.08*	0.08*	0.08*	0.07*	-	-	-	-	-	-	-	-	-
Free Cashflow	347.9%	61.00	14.00	-19.76	27.00	-23.31	-18.37	-85.82	-24.95	61.00	62.00	39.00	37.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.0%	4,378	4,377	4,463	4,471	4,516	4,450	4,590	4,747	1,881	1,839	1,803	1,765	1,764	1,730	1,859	1,817	1,692	1,638	1,623	1,613	1,585
Current Assets	0.2%	1,221	1,219	1,245	1,213	1,235	1,199	1,190	1,174	1,030	1,011	973	928	921	900	1,037	1,002	882	944	930	921	927
Cash Equivalents	28.9%	254	197	196	221	209	244	256	329	553	519	462	424	396	351	446	420	269	316	292	296	345
Inventory	-6.6%	709	760	775	748	696	625	583	536	290	292	300	300	315	322	323	312	338	344	330	322	311
Net PPE	0.7%	613	609	617	624	636	656	668	674	468	458	459	459	467	456	455	456	456	444	437	433	433
Goodwill	1.9%	1,472	1,444	1,464	1,463	1,449	1,370	1,421	1,527	43.00	33.00	33.00	33.00	33.00	33.00	32.00	31.00	31.00	11.00	11.00	11.00	11.00
Current Liabilities	3.8%	482	464	484	462	495	489	486	494	201	185	184	180	195	185	359	357	248	255	260	238	249
Long Term Debt	-100.0%	-	1,589	1,601	1,612	1,624	1,630	1,636	1,642	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	11.6%	51.00	46.00	40.00	35.00	30.00	24.00	19.00	14.00	-	-	-	-	-	-	150	150	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	1,589	1,601	1,612	1,624	1,630	1,636	1,642	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	1.2%	2,123	2,098	2,115	2,100	2,090	2,013	2,086	2,179	1,616	1,590	1,557	1,521	1,502	1,452	1,412	1,376	1,377	1,340	1,318	1,283	1,264
Retained Earnings	-2.1%	808	825	818	828	838	853	866	874	912	892	861	832	809	783	758	739	722	701	675	652	621
Additional Paid-In Capital	0.7%	1,366	1,356	1,345	1,340	1,331	1,323	1,310	1,306	721	711	706	702	693	683	675	666	669	660	658	660	658
Shares Outstanding	0.0%	24.00	24.00	24.00	24.00	24.00	24.00	24.00	24.00	21.00	21.00	21.00	21.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	3,601	-	-	-	-	-	-	-	-	-	-	-	3,306	-	-	-	4,836	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	159.6%	91,269	35,161	-1,474	41,245	-1,711	2,309	-61,385	-1,342	82,621	78,835	54,762	51,320	78,526	75,486	29,221	39,519	48,864	50,796	23,268	-21,010	49,933
Share Based Compensation	-2.4%	10,685	10,947	9,773	9,158	7,428	8,743	7,762	12,092	8,105	6,533	6,681	6,022	5,340	6,265	5,410	6,939	5,757	3,723	6,229	6,209	6,249
Cashflow From Investing	-25.1%	-30,650	-24,508	-17,606	-15,183	-23,998	-12,528	-5,192	-1,867,750	-32,941	-21,086	-17,779	-18,881	-40,903	-24,080	-9,684	-23,472	-100,999	-23,900	-31,476	-10,513	-19,083
Cashflow From Financing	-22.7%	-7,849	-6,396	-5,897	-15,837	-10,385	2,530	-4,030	1,648,917	-15,279	1,108	301	-3,000	4,426	-148,588	5,736	138,386	3,331	93.00	2,901	-17,232	-69.00

ICUI Income Statement

2023-12-31

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
REVENUES:
Revenues	$ 2,259,126	$ 2,279,997	$ 1,316,308
Cost of Goods Sold	1,519,253	1,582,236	824,818
Gross profit	739,873	697,761	491,490
OPERATING EXPENSES:
Selling, general and administrative	606,693	608,345	302,583
Research and development	85,344	92,984	47,498
Restructuring, strategic transaction and integration expenses	41,258	71,421	18,037
Change in fair value of contingent earn-out	(16,247)	(32,091)	0
Contractsettlements	0	0	127
Total operating expenses	717,048	740,659	368,245
Income from operations	22,825	(42,898)	123,245
Interest (Expense) Income, Net	(95,219)	(66,375)	1,982
OTHER EXPENSE, NET	(5,905)	(5,136)	(2,041)
(Loss) Income before income taxes	(78,299)	(114,409)	123,186
Benefit (Provision) for income taxes	48,644	40,123	(20,051)
Net (Loss) Income	$ (29,655)	$ (74,286)	$ 103,135
Basic	$ (1.23)	$ (3.11)	$ 4.86
Diluted	$ (1.23)	$ (3.11)	$ 4.74
WEIGHTED AVERAGE NUMBER OF SHARES
Basic (in shares)	24,091	23,868	21,206
Diluted (in shares)	24,091	23,868	21,781

ICUI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	$ 254,222	$ 208,784
Short-term investment securities	501	4,224
TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES	254,723	213,008
Accounts receivable, net of allowance for doubtful accounts of $11,064 at December 31, 2023 and $8,530 at December 31, 2022	161,566	221,719
Inventories	709,360	696,009
Prepaid income taxes	21,983	15,528
Prepaid expenses and other current assets	73,640	88,932
Total current assets	1,221,272	1,235,196
PROPERTY, PLANT AND EQUIPMENT, net	612,909	636,113
Operating Lease, Right-of-Use Assets	69,909	74,864
Long-term Investment Securities	0	516
GOODWILL	1,472,446	1,449,258
INTANGIBLE ASSETS, net	870,588	982,766
Deferred Income Tax Assets	37,295	31,466
Other Assets	94,020	105,462
TOTAL ASSETS	4,378,439	4,515,641
CURRENT LIABILITIES:
Accounts payable	150,030	215,902
Accrued liabilities	268,215	242,769
Current portion of long-term debt	51,000	29,688
Income tax payable	7,714	6,200
Contingent earn-out liability	4,879	0
Total current liabilities	481,838	494,559
Contingent earn-out liability, Noncurrent	3,991	25,572
Long-Term Debt	1,577,770	1,623,675
Other long-term Liabilities	100,497	114,104
Deferred Income Tax	55,873	126,007
Income Tax Liability	35,060	41,796
COMMITMENTS AND CONTINGENCIES	0	0
STOCKHOLDERS' EQUITY:
Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none	0	0
Common stock, $0.10 par value - Authorized-80,000 shares; Issued 24,144 and 23,995 shares at December 31, 2023 and 2022, respectively, and outstanding 24,141 and 23,993 shares at December 31, 2023 and 2022, respectively.	2,414	2,399
Additional paid-in capital	1,366,493	1,331,249
Treasury Stock, at cost	(262)	(243)
Retained earnings	807,846	837,501
Accumulated other comprehensive loss	(53,081)	(80,978)
Total stockholders' equity	2,123,410	2,089,928
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 4,378,439	$ 4,515,641
Common stock, shares outstanding	24,141,000	23,993,000

About ICU Medical Inc

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 brand; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; professional services; critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

CEO	Mr. Vivek Jain
WEBSITE	icumed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	14500

ICU Medical Inc Frequently Asked Questions

What is the ticker symbol for ICU Medical Inc? What does ICUI stand for in stocks?

ICUI is the stock ticker symbol of ICU Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ICU Medical Inc (ICUI)?

As of Tue Apr 23 2024, market cap of ICU Medical Inc is 2.36 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICUI stock?

You can check ICUI's fair value in chart for subscribers.

What is the fair value of ICUI stock?

You can check ICUI's fair value in chart for subscribers. The fair value of ICU Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ICU Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ICUI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ICU Medical Inc a good stock to buy?

The fair value guage provides a quick view whether ICUI is over valued or under valued. Whether ICU Medical Inc is cheap or expensive depends on the assumptions which impact ICU Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICUI.

What is ICU Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, ICUI's PE ratio (Price to Earnings) is -79.59 and Price to Sales (PS) ratio is 1.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICUI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ICU Medical Inc's stock?

In the past 10 years, ICU Medical Inc has provided 0.057 (multiply by 100 for percentage) rate of return.